Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Through 10b5-1 Plan

Castle Biosciences CEO Derek Maetzold executed sales of common stock on October 14, 2024, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 14, 2024, Derek J Maetzold, the President and CEO of Castle Biosciences Inc. (CSTL), sold shares of common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2024.
• Maetzold sold 1,972 shares directly at a weighted-average price of $32.273.
• Additional sales were made indirectly through various trusts for the benefit of his spouse and children.
• These trusts include The Maetzold Descendants 2020 Trust (1,010 shares), Derek Maetzold 2020 Irrevocable Trust (948 shares), and several Maetzold 2018 Remainder Trusts (299 shares each).
• Following these transactions, Maetzold directly owns 91,664 shares and indirectly owns shares through several trusts, including 122,866 shares via DJM Grantor Retained Annuity Trust No. 5 and 26,134 shares via DJM Grantor Retained Annuity Trust No. 6.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

Insider trading activity is closely monitored in the biotech industry, as it can provide insights into management's perspective on the company's future prospects. Rule 10b5-1 plans are commonly used to mitigate concerns about insider information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates